/IMDX
IMDX Stock - Insight Molecular Diagnostics Inc.
Healthcare|BiotechnologyNASDAQ
$5.41+4.24%
+$0.22 (+4.24%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.65
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.72
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+66.4%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IMDX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.36 – $5.46
TARGET (TP)$9.00
STOP LOSS$4.98
RISK/REWARD1:8.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.19
52W High$8.51
52W Low$1.92
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.88M | $1.50M | $958,000 | $2.20M | $1.22M |
| Gross Profit | $740,000 | $413,000 | $-18,000 | $1.42M | $-639,000 |
| Gross Margin | 39.3% | 27.5% | -1.9% | 64.6% | -52.5% |
| Operating Income | $-61,041,000 | $-25,136,000 | $-17,997,000 | $-53,725,000 | $-29,711,000 |
| Net Income | $-60,663,000 | $-27,781,000 | $-72,902,000 | $-64,097,000 | $-29,932,000 |
| Net Margin | -3225.0% | -1848.4% | -7609.8% | -2916.2% | -2461.5% |
| EPS | $-4.66 | $-3.75 | $-20.00 | $-14.40 | $-9.14 |
Company Overview
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
IMDXBeat Rate
47%
Last 19 quarters
Avg Surprise
-428.8%
EPS vs Estimate
Beats / Misses
9/8
2 met exactly
Latest EPS
$-0.34
Q4 2025
EPS Surprise History
Q1 24
-23.3%
$-1.94vs$-1.57
Q2 24
-68.7%
$-1.13vs$-0.67
Q3 24
+35.7%
$-0.36vs$-0.56
Q4 24
-122.7%
$-0.98vs$-0.44
Q1 25
+211.6%
$0.48vs$-0.43
Q2 25
-8.3%
$-0.26vs$-0.24
Q3 25
-30.4%
$-0.30vs$-0.23
Q4 25
-41.7%
$-0.34vs$-0.24
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.24 | $-0.34 | -41.7% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.23 | $-0.30 | -30.4% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q1 2025 | Mar 24, 2025 | $-0.43 | $0.48 | +211.6% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.44 | $-0.98 | -122.7% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.56 | $-0.36 | +35.7% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.67 | $-1.13 | -68.7% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-1.57 | $-1.94 | -23.3% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-1.52 | $-0.57 | +62.5% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-2.60 | $-1.07 | +58.8% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-2.40 | $-0.80 | +66.7% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | $-0.09 | $-7.64 | -8385.5% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-2.60 | $-1.60 | +38.5% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-2.60 | $-1.40 | +46.2% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-2.60 | $-2.20 | +15.4% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-2.00 | $-2.00 | 0.0% | = MET |
Q4 2021 | Nov 9, 2021 | $-1.40 | $-2.20 | -57.1% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-1.60 | $-1.60 | 0.0% | = MET |
Q2 2021 | May 17, 2021 | $-1.80 | $-0.80 | +55.6% | ✓ BEAT |
Latest News
Needham Maintains Buy on Insight Molecular, Raises Price Target to $9
📈 PositiveBenzinga•Nov 11, 2025, 11:01 AM
Insight Molecular Q3 EPS $(0.34) Misses $(0.21) Estimate, Sales $139.000K Miss $284.000K Estimate
📉 NegativeBenzinga•Nov 10, 2025, 09:06 PM
Insight Molecular Diagnostics Publishes GraftAssure Study In AJT, Demonstrates Assay's Value In Monitoring High-Risk Kidney Transplant Patient
📈 PositiveBenzinga•Oct 6, 2025, 11:20 AM
Insight Molecular Launches 5,000-Patient Registry To Advance Kidney Transplant Rejection Test
📈 PositiveBenzinga•Sep 8, 2025, 11:16 AM
Insight Molecular Diagnostics Enrolls Patients In Its Clinical Trial To Assess GraftAssureDx
📈 PositiveBenzinga•Sep 8, 2025, 11:07 AM
Needham Reiterates Buy on Insight Molecular, Maintains $4.25 Price Target
📈 PositiveBenzinga•Aug 18, 2025, 09:59 AM
Frequently Asked Questions about IMDX
What is IMDX's current stock price?
Insight Molecular Diagnostics Inc. (IMDX) is currently trading at $5.41 per share. The stock has moved +4.24% today.
What is the analyst price target for IMDX?
The average analyst price target for IMDX is $9.00, based on 1 analyst.
What sector is Insight Molecular Diagnostics Inc. in?
Insight Molecular Diagnostics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IMDX's market cap?
Insight Molecular Diagnostics Inc. has a market capitalization of $0.16 billion, making it a small-cap company.
Does IMDX pay dividends?
No, Insight Molecular Diagnostics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.16
Mkt Cap: $0.2B
CCCC
C4 Therapeutics, Inc.
$2.03
Mkt Cap: $0.1B
CDXS
Codexis, Inc.
$1.66
Mkt Cap: $0.1B
CYBN
Cybin Inc.
$7.18
Mkt Cap: $0.4B
IVVD
Invivyd, Inc.
$2.30
Mkt Cap: $0.3B
MIST
Milestone Pharmaceuticals Inc.
$2.15
Mkt Cap: $0.2B
OABI
OmniAb, Inc.
$2.09
Mkt Cap: $0.2B
PEPG
PepGen Inc.
$5.42
Mkt Cap: $0.4B
PRLD
Prelude Therapeutics Incorporated
$2.14
Mkt Cap: $0.2B
SGMO
Sangamo Therapeutics, Inc.
$0.45
Mkt Cap: $0.2B
Explore stocks similar to IMDX for comparison